Use of Glucose-Lowering Medications in Type 2 Diabetes - Full Explanation

This is the ADA (American Diabetes Association) treatment algorithm for managing blood sugar in Type 2 Diabetes (T2D). It is structured around two major goals and several patient-specific complicating factors.

The Foundation (Top of the Chart)

Before any medication is chosen, every patient must have:

Healthy lifestyle behaviors (diet, exercise, smoking cessation)
Diabetes self-management education and support (DSMES)
Attention to social determinants of health (SDOH) - things like income, access to food, housing, and health literacy that directly affect disease control

The teal circle in the top right is a critical reminder: to avoid therapeutic inertia (the tendency to leave ineffective treatment unchanged), clinicians must reassess and modify treatment every 3-6 months.

Two Parallel Goals

The chart splits into two major columns:

Left Column	Right Column
Cardiovascular (CV) and Kidney Risk Reduction	Achievement and Maintenance of Weight and Glycemic Goals

These two arms often work together, but the priority drug choices differ.

LEFT ARM: Cardiovascular & Kidney Risk Reduction

This is where comorbidities drive medication choice. The algorithm asks: What else does this patient have?

1. + ASCVD or High CVD Risk

ASCVD = Atherosclerotic cardiovascular disease (prior heart attack, stroke, peripheral artery disease).

First choice: GLP-1 RA (glucagon-like peptide-1 receptor agonist) with proven CVD benefit - specifically semaglutide or liraglutide (LEADER and SUSTAIN-6 trials showed reduced major cardiac events)
OR: SGLT2i (sodium-glucose cotransporter-2 inhibitor) with proven CVD benefit - specifically empagliflozin or canagliflozin
If blood sugar remains above goal on GLP-1 RA: add SGLT2i, and vice versa
Also consider pioglitazone (a thiazolidinedione with some CV benefit, but use caution - risk of heart failure, bone loss, bladder cancer)

2. + Heart Failure (HF)

SGLT2i with proven HF benefit (empagliflozin, dapagliflozin) - these reduce hospitalizations for both HFrEF (reduced ejection fraction) and HFpEF (preserved ejection fraction)
If blood sugar is still not controlled: add SGLT2i and/or dual GLP-1 RA, particularly agents with proven benefit in symptomatic HFrEF and obesity

3. + Chronic Kidney Disease (CKD)

CKD is defined here as eGFR <60 mL/min/1.73m² OR albuminuria (ACR ≥3.0 mg/mmol / 30 mg/g). Confirmation with repeat measurement is required.

Management is on maximally tolerated dose of ACEi or ARB (standard of care to slow CKD progression), then:

SGLT2i with primary evidence of reducing CKD progression (dapagliflozin - DAPA-CKD trial, canagliflozin - CREDENCE trial)
- Can be started when eGFR ≥20 mL/min/1.73m²
- Glucose-lowering efficacy is reduced when eGFR <45 mL/min/1.73m² (but kidney-protective benefit persists)
OR GLP-1 RA with proven CKD benefit (semaglutide - FLOW trial 2024)
If on SGLT2i and blood sugar still above goal: add a GLP-1 RA, and vice versa

RIGHT ARM: Weight and Glycemic Goals

This column focuses on patients where the primary priority is sugar control or weight loss.

Weight Management

Drugs ranked by efficacy for weight loss:

Tier	Drugs
Very High	Semaglutide, Tirzepatide
High	Dulaglutide, Liraglutide
Intermediate	GLP-1 RA (others), SGLT2i
Neutral	Metformin, DPP-4i

Tirzepatide (a dual GIP/GLP-1 agonist - Mounjaro/Zepbound) produces the most weight loss of any approved medication, up to 20-22% body weight reduction (SURMOUNT trials).

Achievement and Maintenance of Glycemic Goals

Start with Metformin or another agent that provides adequate efficacy. Key principle: prioritize avoidance of hypoglycemia in high-risk individuals (elderly, those prone to falls, those with irregular meals).

Drugs ranked by efficacy for glucose lowering:

Tier	Drugs
Very High	Dulaglutide (high dose), Semaglutide, Tirzepatide, Insulin, Combination oral, Combination injectable (GLP-1 + insulin)
High	GLP-1 RA (other), Metformin, Pioglitazone, SGLT2i, Sulfonylurea
Intermediate	DPP-4i

Bottom of the Chart: Where the Arms Meet

If Additional CV/Kidney Risk Reduction + Glycemic Lowering is Needed

Both arms connect here - the two goals reinforce each other.

+ MASLD / MASH (Liver Disease)

MASLD = Metabolic dysfunction-associated steatotic liver disease (formerly NAFLD) MASH = Metabolic dysfunction-associated steatohepatitis (formerly NASH)

Best agents:

GLP-1 RA, dual GIP/GLP-1 RA (tirzepatide), pioglitazone, or combination of GLP-1 RA + pioglitazone
Insulin is recommended in the specific setting of decompensated cirrhosis (where oral agents may be unsafe)

If Glycemia is Above Goal or Barriers Exist (Right Side Bottom)

Refer to DSMES (diabetes self-management education and support)
Use technology - continuous glucose monitors (CGM), diagnostic tools
Identify and address SDOH barriers

Key Drug Class Summary

Drug Class	Examples	Primary Benefit
GLP-1 RA	Semaglutide, Liraglutide, Dulaglutide	CV protection, weight loss, CKD benefit
SGLT2i	Empagliflozin, Dapagliflozin, Canagliflozin	Heart failure, CKD protection, CV benefit
Dual GIP/GLP-1 RA	Tirzepatide	Maximum weight loss + glucose control
DPP-4i	Sitagliptin, Saxagliptin	Moderate glucose lowering, weight neutral
Metformin	Metformin	First-line, neutral weight, inexpensive
Pioglitazone	Pioglitazone (TZD)	CV benefit, MASLD; risk: fluid retention, fractures
Sulfonylurea	Glipizide, Glimepiride	High glucose lowering; risk: hypoglycemia, weight gain
Insulin	Multiple formulations	Very high glucose lowering; decompensated cirrhosis

The Big Picture: How to Read This in Practice

Every patient gets lifestyle counseling first
Does the patient have ASCVD, HF, or CKD? - If yes, the choice of drug is largely determined by the comorbidity, independent of just sugar control
Is weight a major issue? - Prioritize semaglutide or tirzepatide
Is hypoglycemia a risk? - Avoid sulfonylureas and high-dose insulin; favor GLP-1 RA, SGLT2i, or DPP-4i
Reassess every 3-6 months - do not leave a failing regimen unchanged

The chart reflects a major shift in diabetes care over the past decade: drugs are now chosen based on organ protection (heart, kidneys, liver) first, and glucose-lowering ability second.

This is a shared conversation. Sign in to Orris to start your own chat.